Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

96.50EUR
4:16pm GMT
Change (% chg)

€0.90 (+0.94%)
Prev Close
€95.60
Open
€96.14
Day's High
€97.12
Day's Low
€95.48
Volume
249,502
Avg. Vol
559,951
52-wk High
€100.20
52-wk Low
€74.54

Latest Key Developments (Source: Significant Developments)

Merck And Pfizer Provide Update On Avelumab In Platinum-Resistant/Refractory Ovarian Cancer
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Merck KGaA ::MERCK AND PFIZER PROVIDE UPDATE ON AVELUMAB IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER.MERCK KGAA - SIGNALS WERE OBSERVED IN THE COMBINATION ARM RELATIVE TO PLD, AND FURTHER ANALYSES OF TRIAL ARE WARRANTED.MERCK - PHASE III JAVELIN OVARIAN 200 TRIAL DID NOT MEET PRESPECIFIED PRIMARY ENDPOINTS.MERCK KGAA - NO NEW SAFETY SIGNALS WERE OBSERVED FOR AVELUMAB ALONE OR IN COMBINATION.MERCK KGAA - SAFETY PROFILE FOR AVELUMAB IN TRIAL WAS CONSISTENT WITH OBSERVED IN OVERALL JAVELIN CLINICAL DEVELOPMENT PROGRAM.MERCK - STUDY RESULTS INDICATE POTENTIAL CLINICAL ACTIVITY OF COMBINATION OF AVELUMAB & CHEMOTHERAPY.  Full Article

Merck KGaA Phase III Javelin Ovarian 200 Trial Did Not Reach Endpoints
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Merck Kgaa AND PFIZER ::PHASE III JAVELIN OVARIAN 200 TRIAL EVALUATING AVELUMAB* ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD), DID NOT MEET PRESPECIFIED PRIMARY ENDPOINTS OF OVERALL SURVIVAL (OS) OR PROGRESSION-FREE SURVIVAL (PFS) IN PATIENTS WITH PLATINUM-RESISTANT OR -REFRACTORY OVARIAN CANCER.DATA ARE CURRENTLY BEING ANALYZED, AND DETAILED RESULTS WILL BE SHARED WITH SCIENTIFIC COMMUNITY.RESEARCHER SAYS ALTHOUGH OS AND PFS DID NOT REACH STATISTICAL SIGNIFICANCE, STUDY RESULTS INDICATE POTENTIAL CLINICAL ACTIVITY OF COMBINATION OF AVELUMAB AND CHEMOTHERAPY WHICH WILL BE ANALYZED FURTHER.  Full Article

EMD Serono says Mavenclad Gets Positive CADTH Canadian Drug Committee Recommendation
Monday, 29 Oct 2018 

Oct 29 (Reuters) - EMD SERONO::MAVENCLAD (CLADRIBINE TABLETS) RECEIVES POSITIVE CADTH CANADIAN DRUG EXPERT COMMITTEE (CDEC) RECOMMENDATION.  Full Article

Merck: FDA Accepts File For Cladribine Tablets As Potential Treatment For Relapsing Forms Of Multiple Sclerosis
Monday, 30 Jul 2018 

July 30 (Reuters) - MERCK KGAA ::FDA ACCEPTS FILE FOR CLADRIBINE TABLETS AS POTENTIAL TREATMENT FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS.NEW DRUG APPLICATION INCLUDES CLOSE TO 12,000 PATIENT YEARS OF DATA AND UP TO 10 YEARS OF SAFETY DATA IN SOME PATIENTS.  Full Article

FDA Accepts File For Cladribine Tablets As Potential Treatment For Relapsing Forms Of Multiple Sclerosis
Monday, 30 Jul 2018 

July 30 (Reuters) - Merck KGaA ::FDA ACCEPTS FILE FOR CLADRIBINE TABLETS AS POTENTIAL TREATMENT FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS.EMD SERONO - RESUBMISSION OF NEW DRUG APPLICATION FOR CLADRIBINE TABLETS.EMD SERONO - RESUBMISSION FOR CLADRIBINE TABLETS AS POTENTIAL TREATMENT FOR RELAPSING FORMS OF MS ACCEPTED FOR FILING BY FDA.  Full Article

RBK EMD raises 7 bln won in private placement
Friday, 27 Jul 2018 

July 27 (Reuters) - RBK EMD Co Ltd <106080.KQ> ::Says it raised 7 billion won in private placement of 12,367,491 shares of the company.  Full Article

Merck KGaA Performance Materials CEO Says Doesn't Rule Out Smaller M&A
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Merck KGaA Performance Materials division CEO::SAYS BIG ACQUISITIONS WON'T HAPPEN UNTIL AFTER 2019, BUT CANNOT RULE OUT SMALLER ONES BEFORE THEN.SAYS DOESN'T SEE NEGATIVE IMPACT FROM U.S.-CHINA TRADE TARIFFS, MERCK DOESN'T HAVE MATERIAL STREAMS ACROSS AFFECTED REGIONS.  Full Article

Merck KGaA Receives Patent For CRISPR Technology In China
Monday, 23 Apr 2018 

April 23 (Reuters) - Merck KGaA ::MERCK RECEIVES PATENT FOR CRISPR TECHNOLOGY IN CHINA.  Full Article

P&G Acquires the Consumer Health Business Of Merck KGaA, Darmstadt, Germany
Thursday, 19 Apr 2018 

April 19 (Reuters) - Procter & Gamble Co ::ACQUIRES THE CONSUMER HEALTH BUSINESS OF MERCK KGAA, DARMSTADT, GERMANY.SAYS ANNOUNCED IT HAS SIGNED AN AGREEMENT TO ACQUIRE CONSUMER HEALTH BUSINESS OF MERCK KGAA, DARMSTADT, GERMANY.HAS SIGNED AGREEMENT TO ACQUIRE CONSUMER HEALTH BUSINESS OF MERCK KGAA, FOR PURCHASE PRICE OF ABOUT 3.4 BILLION EURO.  Full Article

P&G Nears Deal To Acquire Merck KGaA's Consumer-Health Unit - WSJ
Thursday, 19 Apr 2018 

April 18 (Reuters) - :P&G NEARS DEAL TO ACQUIRE MERCK KGAA’S CONSUMER-HEALTH UNIT - WSJ, CITING SOURCES.  Full Article

Photo

Big pharma leaves big gaps: drugmakers urged to do more for poor

LONDON Many of the world's top drugmakers are not doing enough to provide medicines to poor countries, leaving big gaps in access to treatments in crucial disease areas, including cancer, according to a new report on Tuesday.